Nodular Prurigo Market Report 2026

Nodular Prurigo Market Overview

• Nodular Prurigo market size has reached to $1.25 billion in 2025 • Expected to grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Increasing Demand For Targeted Therapies Fueling The Growth Of The Market Due To Their Precision And Improved Patient Outcomes • Market Trend: Emerging Targeted Therapies Reshaping The Treatment Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nodular Prurigo Market?

Nodular prurigo, also known as prurigo nodularis, is a chronic skin condition marked by intensely itchy, firm nodules that commonly appear on the arms, legs, and torso. Nodular prurigo is a chronic skin condition of unclear cause involving immune, nerve, and inflammatory factors where persistent itching leads to excessive scratching, worsening the condition and causing scarring, and typically requires long-term dermatological management. The main types of nodular prurigo are chronic nodular prurigo, acute nodular prurigo, and subacute nodular prurigo. Chronic nodular prurigo refers to a long-lasting form of prurigo characterized by the development of intensely itchy, firm nodules or bumps on the skin. These are used for various treatment types, including topical treatments, systemic treatments, phototherapy, and immunosuppressants. The various patient demographics include adults, children, and the elderly and are used by various end users such as hospitals, homecare, specialty clinics, and others.

What Is The Nodular Prurigo Market Growth Forecast?

The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising development of novel biologics and monoclonal antibodies, increasing focus on personalized dermatology treatments, growing investments in inflammatory skin disease research, expansion of advanced immunotherapy pipelines, increasing demand for long-term itch control solutions. Major trends in the forecast period include increasing adoption of targeted immunomodulatory therapies, rising use of biologic treatments for chronic pruritus, growing focus on neuropathic itch management, expansion of long-term disease management protocols, enhanced emphasis on patient-centric dermatology care.

Global Nodular Prurigo Market Segmentation

1) By Type: Chronic Nodular Prurigo, Acute Nodular Prurigo, Subacute Nodular Prurigo 2) By Treatment Type: Topical Treatments, Systemic Treatments, Phototherapy, Immunosuppressants 3) By Patient Demographics: Adults, Children, Elderly 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo, Secondary To Dermatologic Conditions, Neuropathic Causes, Systemic Disease-Associated, Psychogenic Prurigo 2) By Acute Nodular Prurigo: Insect Bite-Induced, Allergic Reactions, Drug-Induced Prurigo, Infectious Triggers 3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo, Post-Inflammatory Prurigo, Transient Dermatoses, Reaction To Environmental Irritants

What Is The Driver Of The Nodular Prurigo Market?

The increasing demand for targeted therapies is expected to propel the growth of the nodular prurigo market going forward. Targeted therapies refer to the medical treatments that specifically target and interfere with molecular pathways involved in the growth and spread of diseases. The rising demand for targeted therapies can be due to their ability to provide more precise treatments with fewer side effects, improving patient outcomes and offering alternatives to traditional, less specific therapies. Nodular prurigo helps drive the development of targeted therapies by presenting a clear unmet medical need involving specific immune pathways such as IL-4, IL-13, and IL-31, which enables the use of biologics that precisely block these inflammatory signals for more effective treatment. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, in Q4 2023, the number of gene therapies in Phase III increased by 10% from the previous quarter, marking the first rise since Q3 2022. Therefore, the increasing demand for targeted therapies is driving growth in the nodular prurigo industry.

Key Players In The Global Nodular Prurigo Market

Major companies operating in the nodular prurigo market are Merck and Co Inc, Sanofi SA, GlaxoSmithKline plc, Amgen Inc, Regeneron Pharmaceuticals Inc, Astellas Pharma Inc, Sun Pharmaceutical Industries Limited, Galderma SA, Incyte Corporation, Kyowa Kirin Co Ltd, LEO Pharma AS, Maruho Co Ltd, Kiniksa Pharmaceuticals Ltd, Keymed Biosciences Co Ltd, Trevi Therapeutics Inc, Menlo Therapeutics Inc, VYNE Therapeutics Inc, Celldex Therapeutics Inc, AbbVie Inc, Pfizer Inc, Novartis AG, Eli Lilly and Company

Global Nodular Prurigo Market Trends and Insights

Major companies operating in the nodular prurigo market are focusing on developing innovative solutions, such as anti-IL-31 receptor biologic, to meet the rising demand for disease-modifying therapies that reduce intense chronic itch, improve nodule resolution, and lower reliance on long-term topical corticosteroids and broad immunosuppressants. An anti-IL-31 receptor monoclonal antibody is a biologic therapy composed of engineered humanized antibodies that bind the IL-31 receptor A on sensory and immune cells, blocking IL-31 signaling which is implicated in chronic pruritus. For instance, in August 2024, Galderma S.A., a Switzerland-based dermatology pharmaceutical company, launched Nemluvio (nemolizumab), an innovative anti-IL-31 receptor monoclonal antibody for adults living with prurigo nodularis. Nemluvio (nemolizumab) is a humanized monoclonal antibody formulated for subcutaneous injection that binds IL-31 receptor A to interrupt itch signaling and downstream inflammatory pathways; it was developed to reduce intense chronic itch and promote healing of pruritic nodules, and is supplied as an autoinjector for outpatient use. Unique features include its targeted mechanism, systemic activity suitable for widespread disease, and a dosing format intended to improve patient adherence compared with clinic-only infusions.

What Are Latest Mergers And Acquisitions In The Nodular Prurigo Market?

In April 2024, Incyte Corporation, a US-based pharmaceutical company, partnered with China Medical System Holdings Limited to advance treatments for various autoimmune and inflammatory dermatologic conditions, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria. China Medical System Holdings Limited is a Hong Kong-based pharmaceutical company that is involved in nodular prurigo treatment.

Regional Outlook

North America was the largest region in the nodular prurigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nodular Prurigo Market?

The nodular prurigo market consists of revenues earned by entities by providing services such as diagnosis and clinical evaluation, prescription of topical treatments, phototherapy, biologic therapies, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The nodular prurigo market also includes sales of products including oral antidepressants, JAK inhibitors, and topical calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nodular Prurigo Market Report 2026?

The nodular prurigo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nodular prurigo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.